CD14 and colorectal adenocarcinoma: As the activity of enhancers is known to be cell type-specific [19], we assayed chromatin interactions in monocytes (i.e. CD14+ fraction of PBMCs), lymphocytes (i.e. CD14- fraction of PBMCs), and in an intestinal epithelial cell line (DLD-1, derived from colorectal adenocarcinoma).